Amgen and Advaxis enter global cancer immunotherapies collaboration

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient’s immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient’s tumor. http://www.worldpharmanews.com/amgen/3588-amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration